JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M207484200 on October 8, 2002

J. Biol. Chem., Vol. 277, Issue 51, 49417-49421, December 20, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/51/49417    most recent
M207484200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caillaud, A.
Right arrow Articles by Marié, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caillaud, A.
Right arrow Articles by Marié, I.

Acetylation of Interferon Regulatory Factor-7 by p300/CREB-binding Protein (CBP)-associated Factor (PCAF) Impairs its DNA Binding*

Alexandre CaillaudDagger §, Arun Prakash, Eric Smith, Atsuko Masumi||, Ara G. HovanessianDagger , David E. Levy, and Isabelle MariéDagger **

From the Dagger  Unité de Virologie et Immunologie Cellulaire, Institut Pasteur, 75724 Paris, France, the  Department of Pathology and Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, and the || National Institute of Infectious Diseases, Tokyo 208-0011, Japan

Received for publication, July 25, 2002, and in revised form, September 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interferon regulatory factor 7 (IRF7) is an interferon-inducible transcription factor required for induction of delayed early interferon alpha  genes and the onset of a potent antiviral state. After induction of IRF7 by autocrine interferon, latent IRF7 is activated by virus-induced phosphorylation on serine residues within the C-terminal regulatory domain. Although it is likely that IRF7 is subjected to a cascade of events responsible for regulating its biological activity, to date no mechanism other than phosphorylation has been reported to modulate IRF7 activity. Here, we report that IRF7 is acetylated in vivo by the histone acetyltransferases p300/CBP-associated factor (PCAF) and GCN5. The single lysine residue target for acetylation, lysine 92, is located in the DNA-binding domain and is conserved throughout the entire IRF family. Mutation of lysine 92 resulted in complete abolition of DNA binding ability. However, a mutant that cannot be acetylated by PCAF due to a change in the surrounding amino acid context of lysine 92 showed increased DNA binding and activity compared with wild type IRF7. Conversely, we showed that acetylated IRF7 displayed impaired DNA binding capability and that over-expression of PCAF led to decreased IRF7 activity. Together, our results strongly suggest that acetylation of lysine 92 negatively modulates IRF7 DNA binding.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interferon regulatory factors (IRF)1 are a growing family of transcription factors that have been implicated in antiviral defense, cell growth, and immune regulation (for review, see Ref. 1). Ten members of the family have been identified so far: IRF1, IRF2, IRF3, IRF4/Pip/ISCAT, IRF5, IRF6, IRF7, IRF8/ICSBP, IRF9/p48, and the recently cloned avian IRF10. In addition there are at least four more distantly related viral homologues encoded by human herpes virus 8 (HHV8) (2, 3). This family is mainly defined by a highly conserved amino-terminal DNA-binding domain (DBD) characterized by a repeat containing five tryptophan residues that shows similarities with the c-myb proto-oncogene DBD (4). Two closely related members of this family, IRF3 and IRF7, have been identified as direct transducers of virus-mediated signaling and were shown to play an essential role in the induction of type I interferon (IFN) (5-8). Previous studies (5-12) have clearly established that IRF3 and IRF7 activity is regulated by virally induced phosphorylation of serine residues located in their C terminus. Phosphorylation induces allosteric changes that result in dimerization and facilitate nuclear retention, derepress transactivation, and allow specific DNA binding (9, 10).

Despite the important similarities among IRF family proteins, each provides a unique biological function. For instance, although both IRF3 and IRF7 are involved in IFN gene expression during viral infections, IRF3 targets specifically IFNbeta and alpha 4 (5). In contrast, IRF7 is required for the induction of additional members of the IFNalpha multi-gene family (5, 11, 12). Although there are several structural differences between IRF3 and IRF7 that could account for this difference, the major determinant appears to be DNA binding specificity. IRF3 binds with high affinity to relatively perfect GAA repeat motifs found within the positive regulatory domain I of the IFNbeta promoter and the IFNalpha 4 promoter; in contrast, IRF7 displays a more relaxed DNA binding specificity allowing it to bind variant sequences found in promoters of the other IFNalpha genes (13). However, the structural basis for differential DNA binding has not been elucidated.

Posttranslational modifications in addition to phosphorylation have been found to modulate transcription factor activity, including effects on DNA binding affinity. Histone acetyltransferases (HAT) are increasingly being recognized as modifiers of non-histone proteins, and there is a growing body of evidence supporting the notion that acetylation, like phosphorylation, is an important regulatory protein modification (for review, see Ref. 14). There are now several reported families of acetylases exemplified by PCAF/GCN5, p300/CBP, TAF250, SRC1, and MOZ (for review, see Ref. 15). Of these proteins, two families, PCAF/GCN5 and p300/CBP, are the most characterized and potent acetylases compared with other families. HATs function enzymatically by transferring an acetyl group from acetyl-coenzyme A (acetylCoA) to the epsilon  amino group of certain lysine side chains. Transcription factors that have been shown to be acetylated by different HAT proteins include p53, MyoD, HNF4, E2F1, and c-Myb. These acetylation events have been shown to directly affect protein function. The consequence of acetylation on protein function is highly variable from one protein to another and depends on where within the protein the acetylation takes place. For p53 and E2F1, for example, acetylation regulates DNA binding (16, 17). Besides affecting DNA binding, acetylation has also been reported to modulate protein-protein interactions. For example, the association of nuclear receptors with their co-activator ACTR is inhibited by acetylation (18). Protein stability is the third characteristic to be altered by acetylation. Increased stability has been correlated with acetylated E2F1 and alpha -tubulin (17, 19).

Because of the potential of lysine acetylation to modulate DNA binding, we investigated the possible acetylation of IRF7. Here we show that IRF7 is subject to acetylation by the HAT of the PCAF/GCN5 family in vivo. We mapped the acetylation site to a unique lysine residue in the DBD at position 92. Using different point mutants, we provide evidence that this residue is within a region that distinguishes IRF3 and IRF7 DNA binding affinity and is essential for DNA binding. Finally we show that acetylation leads to impaired DNA binding of IRF7 to its cognate DNA.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture, Transfections, and Viral Infections-- Human embryonic kidney 293T cells and monkey kidney COS cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. DNA transfections of 293T and COS cells were performed by standard methods using calcium phosphate. Newcastle disease virus (NDV), Manhattan strain, was grown in 10-day embryonated chicken eggs, and viral infections were performed as previously described (5). Rabbit and mouse antibodies to FLAG were obtained from Zymed Laboratories Inc. and Sigma, respectively. Rabbit polyclonal antibodies to acetylated lysines were obtained from Cell Signaling, and rabbit antibodies to IRF7 were from Zymed Laboratories Inc..

Electromobility Shift Assays (EMSAs) and Affinity DNA Binding Assays-- EMSAs were performed by incubating nuclear extracts of each sample (2 µg), prepared as previously described (20), with a labeled double stranded oligonucleotide containing an IFN-stimulated response element (ISRE) sequence derived from the ISG15 gene (21). The DNA binding affinity assay was performed as follows. Purified GST-IRF7DBD was mixed with 100 ng of purified recombinant PCAF in the presence of 100 µM acetylCoA for 30 min at 30 °C. Different amounts of the reaction mixture were then incubated with biotinylated DNA derived from the ISG15 gene. Bound materials were purified with streptavidin beads and revealed by immunoblotting using anti-IRF7 antibodies.

Dissociation Rate Determination-- Dissociation rates of protein-DNA complexes were determined essentially as described (22) using nuclear extracts from cells over-expressing IRF7WT or IRF7GTTR. The approximate half-life of the complex was determined by quantitative phosphorimaging

Plasmids and Constructs-- Expression constructs for PCAF and GCN5 were kindly provided by Y. Nakatani and R. Schiltz (National Institutes of Health, Bethesda, MD) and S. Roth (M. D. Anderson Cancer Center). The PCAF HAT mutant was provided by M. Rosenfeld. The GCN5 HAT mutant was described previously (23). Histone deacetylase 1 expression construct was obtained from E. Verdin (Gladstone Institute, San Francisco, CA). IRF7 KR (K92R) and GTTR (G91T/T93R) mutants were generated by site directed mutagenesis (Stratagene) and confirmed by DNA sequencing. Mutants of IRF7 Delta 1-4 have been described elsewhere (10). GST-IRF7DBD was generated by cloning the first 256 amino acids of IRF7 into the pGEX-2T vector using the BamHI and EcoRI sites.

Reporter Assays-- Luciferase activities were measured in cell lysates using commercial reagents as recommended by the manufacturer (Promega) and were normalized to beta -galactosidase activity of a co-transfected CMV-lacZ plasmid measured on a luminescent substrate. Each construct was tested in duplicate in at least three independent experiments. Results shown are from a single experiment representative of results obtained.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IRF7 Is Acetylated in Vivo by PCAF and GCN5-- It has now been clearly demonstrated that virus-induced phosphorylation of IRF7 is an essential event for its activation (10, 13). We investigated other potential posttranslational modifications that may influence IRF7 activity. Recently, two other IRF family members, IRF1 and IRF2, have been shown to be acetylated by p300 and to a lesser degree by PCAF (24). To test whether IRF7 was acetylated in vivo, FLAG-tagged IRF7 was transfected and IRF7 was detected using an anti-acetylated lysine antibody after the extracts had been subjected to immunoprecipitation with anti-FLAG antibodies. As previously observed, a slower migrating form of IRF7 corresponding to phosphorylated IRF7 was detected in NDV-infected extracts in addition to the latent IRF7 found in control extracts (5). Acetylated IRF7 could be observed in both NDV-infected and uninfected extracts, indicating that IRF7 is basally acetylated in the cell (Fig. 1A). To identify the enzyme responsible for IRF7 acetylation, a set of acetyltransferases (p300, GCN5, and PCAF) as well as the corresponding enzymatically inactive mutants (HAT mutants), were co-transfected with FLAG-tagged IRF7 in 293T cells. IRF7 was immunoprecipitated with anti-FLAG antibodies and subjected to an anti-acetylated lysine Western blot analysis to detect its level of acetylation (Fig. 1B). Co-transfection of active PCAF resulted in a significant acetylation of IRF7 that was not observed when the HAT mutant form of PCAF was co-transfected. A darker exposure of the gel showed that IRF7 was also basally acetylated in the absence of transfected HAT proteins, although this acetylation was much weaker (data not shown). As previously described, we observed a strong auto-acetylation of PCAF (25). Similarly, GCN5, but not the GCN5 HAT mutant, was able to acetylate IRF7 though to a much lesser extent than PCAF. In contrast, p300 did not cause IRF7 acetylation (data not shown). All three HAT proteins were active in that they were able to acetylate endogenous substrates in vivo in transfected cells (data not shown). Furthermore, over-expression of histone deacetylase 1 along with IRF7 and PCAF led to a significant decrease of the amount of acetylated IRF7. Taken together, these results show that IRF7 is subjected to reversible acetylation in vivo.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   In vivo acetylation of IRF7 by PCAF and GCN5. A, 293T cells were transfected with FLAG-tagged IRF7 and, after 16 h, were mock-infected or infected with NDV for 7 h, as indicated. Nuclear extracts were immunoprecipitated with anti-FLAG antibodies and analyzed by Western blotting with anti-acetyl lysine antibodies. In the lower panel the same membrane re-blotted with anti-IRF7 antibodies is shown. B, 293T cells were transfected with FLAG-tagged IRF7 along with different expression constructs coding for histone acetyltransferases (FLAG-tagged PCAF and FLAG-tagged GCN5) or their corresponding inactive forms (HAT mutants) and histone deacetylase 1, as indicated. Whole cell extracts were immunoprecipitated with the anti-FLAG antibody M2 and analyzed by Western blotting with anti-acetylated lysine antibodies (upper panel). As a loading control, 10% of the extracts used for immunoprecipitation were subjected to direct immunoblotting using anti-FLAG antibodies (lower panel). Respective sizes of PCAF, GCN5, and IRF7 are indicated on the right.

Lysine 92 Is the Unique Target for Acetylation by PCAF-- To map the acetylation site(s), we co-transfected a series of deletion mutants of IRF7 along with PCAF in 293T cells. As shown in Fig. 2A (right panel), all the deletion mutants tested except Delta 2, which is missing the DNA-binding domain, could still be acetylated by PCAF. Interestingly, the mutant Delta 1, missing only part of the DNA-binding domain, was strongly acetylated. As mentioned above, acetylation occurs only on lysine residues, and only two lysine residues were found in the sequence of Delta 1 that is missing in Delta 2, at positions 43 and 92. Each lysine residue was individually mutated to arginine and the point mutants were tested for their ability to become acetylated by over-expressed PCAF. As shown in Fig. 2A (right panel), the mutant K92R lost its ability to be acetylated, whereas K43R was acetylated as strongly as WTIRF7. Although we cannot exclude the possibility that lysine 92 substitution to arginine alters the recognition of IRF7 by PCAF, this result strongly suggests that IRF7 is acetylated by PCAF on residue 92. As expected, the double mutant K43R/K92R was also unable to be acetylated. Interestingly, lysine residue 92 is conserved throughout the IRF family, suggesting that it plays a fundamental role in transcription factor function (Fig. 2B).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Acetylation maps to lysine 92 in the DNA-binding domain. A, 293T cells were transfected with different FLAG-tagged deletion and point mutants (Lys to Arg) of IRF7 along with FLAG-tagged PCAF as indicated (see schematic representation of IRF7 deletion mutants on the left part of the figure). Whole cell extracts were immunoprecipitated with the anti-FLAG antibody M2 and analyzed by Western blotting with anti-acetylated lysine antibodies (upper panel). As a loading control, 10% of the extracts used for immunoprecipitation were monitored by Western blotting using anti-FLAG antibodies (lower panel). Respective sizes of PCAF, GCN5, and IRF7 are indicated on the right. B, sequence comparison of the surrounding sequence of lysine 92 with the sequence of the other murine members of the family. The conserved lysine (corresponding to lysine 92 in IRF7) is highlighted in bold.

Lysine 92 Is a Residue Critical for DNA Binding-- To characterize the role of lysine 92 in IRF7 function, we tested the ability of the K92R mutant to transactivate a typical IFNalpha gene promoter in a reporter assay. As depicted in Fig. 3A, K92R was completely devoid of activity on the IFNalpha 6 promoter, whereas WT-IRF7 activated this promoter over 1000-fold following viral infection. However, the absence of activity could be due to impaired DNA binding rather than to the inability of the mutant to be acetylated. Indeed, as described for many other DNA-binding proteins, charged lysines are crucial for stabilizing DNA-protein complexes. To test this hypothesis, we investigated the DNA binding ability of the K92R mutant by electromobility shift assay on an ISRE probe. As shown in Fig. 3B, the K92R mutant was unable to bind DNA (compare lanes 3 and 4 with lanes 7 and 8).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   IRF7 K92R is devoid of activity and does not bind DNA. A, COS cells were transfected with WT-IRF7 and IRF7K92R (as indicated) along with a luciferase reporter driven by the IFNalpha 6 promoter. At 24 h after infection, cells were mock-infected (black bars) or infected with NDV (gray bars) for 12 h. Mean values from a representative experiment are expressed as fold induction relative to cells transfected with an empty vector after normalization to co-transfected beta -galactosidase. B, EMSA was performed on nuclear extracts derived from 293T cells transfected with an empty vector or WT-IRF7 or IRF7K92R mutant and PCAF that had been mock-infected or infected with NDV for 7 h, as indicated. Extracts were incubated with an ISRE probe from the ISG15 gene. C, IRF7K92R is phosphorylated following infection by NDV. 293T cells were transfected with WT-IRF7 or IRF7K92R. Nuclear extracts were harvested after 7 h of mock or NDV infection and analyzed for electrophoretic mobility by Western blotting using anti-FLAG antibodies.

Because DNA binding ability of WT-IRF7 is dramatically increased upon virus-induced phosphorylation, it was important to ascertain whether the K92R mutant was phosphorylated in virus-infected cells. The presence of phosphorylated K92R mutant was monitored by the detection of a slower migrating band after immunoblotting of virus-infected cell extracts as observed for WT-IRF7. Fig. 3C shows that K92R was phosphorylated in virus-infected cells. The slight diminution in phosphorylation compared with WTIRF7 is unlikely to account for the major difference observed in DNA binding.

Acetylation Inhibits IRF7 DNA Binding and Activity-- The abolition of DNA binding of the K92R mutant suggested that this lysine might play a crucial role for DNA binding independently of its acetylation status. To circumvent this problem, we sought to design an IRF7 mutant that could not be acetylated but retained DNA binding ability. In the course of understanding the structural determinants driving acetylation by PCAF, the acetylation status of the closely functionally and structurally related protein IRF3 was determined. Despite the close identity between the two proteins, no acetylation of IRF3 was detected in the presence of PCAF (see Fig. 4B, right panel, lane 6). Taking advantage of this observation, we designed a mutant where the amino acids surrounding the lysine acetylation target were changed into those of IRF3 (G91T/T93R) (Fig. 4A). First, we verified that G91T/T93R had lost its ability to be acetylated by PCAF, as intended. GTTR showed an undetectable level of acetylation, comparable with IRF3 or IRF7 deletion mutant Delta 2 (Fig. 4B, compare lane 2 with lanes 4 and 6). This observation proved that the sequence context of the target lysine is a determinant for its acetylation by PCAF. Second, we tested whether this mutant retained DNA binding ability. GTTR was still able to bind DNA, although it exhibited an altered pattern in electromobility shift assay on an ISRE probe compared with WT-IRF7 (Fig. 4C). In a reporter assay using the IFNalpha 6 promoter, the IRF7GTTR mutant was over 30-fold more active than WT-IRF7 in control cells and over 5-fold more active after viral infection (Fig. 4D). Thus, this double point mutant of IRF7, which cannot be acetylated, displayed enhanced transcriptional activity. These results strongly suggested that acetylation of lysine 92 imposes an inhibitory effect on IRF7 activity. To confirm that this effect was due to acetylation, it was important to verify that over-expression of PCAF had no effect on IRF7GTTR DNA binding. As shown above (Fig. 3B, lanes 5 and 6), over-expression of PCAF led to decreased DNA binding activity, whereas over-expression of the PCAF HAT mutant had no effect on IRF7 DNA binding (Fig. 4E, left panel). In contrast, the IRF7GTTR mutant was not affected by PCAF over-expression, strongly suggesting that the inhibition of IRF7 DNA binding by PCAF was due to acetylation of lysine 92 (Fig. 4E, right panel). However, the slight difference in DNA binding affinity between WT-IRF7 and IRF7GTTR was unlikely to account for the substantial difference observed in the transactivation activity assay. To explore possible reasons for the increased transactivation ability of IRF7GTTR, the stability of the IRF7GTTR and WT-IRF7 protein-DNA complexes were compared. The dissociation rate of each complex was measured by challenging the preformed complexes with a 500-fold molar excess of unlabelled ISRE oligonucleotide. Half-lives of the complexes were calculated by removing aliquots at serial time points and loading them onto a running non-denaturing polyacrylamide gel. Dissociation of WT-IRF7 from DNA was very rapid (<1 min), whereas the IRF7GTTR-ISRE interaction was strikingly more stable, with a half-life of around 60 min (Fig. 4F). This indicates that the non-acetylatable IRF7GTTR mutant has a substantially higher affinity for the ISRE, suggesting that acetylation strongly impairs IRF7 affinity for its cognate DNA. Interestingly, IRF3 complexes also showed a very high affinity for the ISRE element, consistent with the finding that IRF3 is not acetylated by PCAF (data not shown).


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 4.   IRF7GTTR mutant exhibits increased DNA binding and activity. A, sequence of the IRF7GTTR mutant is shown and compared with murine IRF3 and IRF7. B, 293T cells were transfected with FLAG-tagged WT-IRF7, IRF7GTTR, IRF7Delta 2, and IRF3 along with FLAG-tagged PCAF, as indicated. Whole cell extracts were immunoprecipitated with the anti-FLAG antibody M2 and analyzed by Western blotting with anti-acetylated lysine antibodies (upper panel). In the lower panel the same membrane blotted with polyclonal anti-FLAG antibodies is shown. The respective sizes of PCAF, IRF7, and IRF3 are indicated on the right. * indicates some nonspecific bands (the apparent molecular weights of IRF7 Delta 2 and IRF3 are smaller as shown in the lower panel). C, EMSA was performed on nuclear extracts derived from 293T cells transfected with an empty vector or WT-IRF7 or IRF7GTTR mutant that had been mock- or NDV-infected for 7 h, as indicated. Extracts were incubated with an ISRE probe from the ISG15 gene. D, COS cells were transfected with WT-IRF7 and IRF7GTTR (as indicated) along with a luciferase reporter driven by the IFNalpha 6 promoter. At 24 h after infection, cells were mock- (black bars) or NDV-infected (gray bars) for 12 h. Mean values from a representative experiment are expressed as fold induction relative to cells transfected with an empty vector after normalization to co-transfected beta -galactosidase. E, EMSA was performed on nuclear extracts derived from 293T cells transfected with an empty vector or WT-IRF7 or IRF7GTTR mutant, along with PCAF when indicated, that had been mock- or NDV-infected for 7 h, as indicated. Extracts were incubated with an ISRE probe from the ISG15 gene. F, protein-DNA complexes between IRF7WT or IRF7GTTR and a labeled ISRE probe were formed using standard EMSA conditions. The stability of these complexes was determined by measuring the amount of residual labeled DNA bound to the proteins at indicated times (in min) following addition of unlabeled ISRE nucleotide. Samples were loaded at differing times throughout the experiment and were therefore electrophoresed for different lengths of time, resulting in somewhat different mobilities of the same complexes.

To directly assess whether acetylation had an inhibitory effect on DNA binding, purified GST-IRF7 was acetylated in vitro by PCAF prior to incubation with biotinylated ISRE. ISRE-bound IRF7 was then purified and detected by immunoblotting. As shown in Fig. 5A, acetylated IRF7 displayed decreased DNA affinity when compared with non-acetylated IRF7. Greater than 3-fold more IRF7 was recovered in the DNA-bound fraction in the absence of acetylation (compare the -AcetylCoA panel to the +AcetylCoA panel). This result is consistent with the finding that over-expression of PCAF led to reduced DNA binding in an electromobility shift assay, as shown in Fig. 3B (compare lanes 5 and 6 to lanes 3 and 4). To test whether acetylation-dependent inhibition of DNA binding impairs IRF7 activity, we co-transfected increasing amounts of PCAF along with IRF7 in a reporter assay. We observed a dose-dependent inhibition of IRF7-mediated activation of the IFNalpha 6 promoter in infected cells (Fig. 5B). The 2-3-fold inhibition observed in this assay correlates with the fold inhibition detected in the DNA affinity assay. Taken together, our results strongly suggest that acetylation of IRF7 by PCAF is a reversible mechanism that modulates IRF7 DNA binding and activity and targets a region that distinguishes IRF7 from its relative IRF3.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Acetylation is detrimental to IRF7 DNA binding and activity. A, purified GST-IRF7 DBD was acetylated in vitro by PCAF in the presence or absence of acetylCoA, as indicated, prior to incubation of the indicated amounts of GST-IRF7 with biotinylated ISRE derived from the ISG15 gene. Bound IRF7 was purified using streptavidin beads and detected by immunobloting using anti-IRF7 antibodies. B, COS cells were co-transfected with WT-IRF7 (100 ng) and increasing amounts of PCAF (0, 1000, and 2000 ng) along with a luciferase reporter driven by the IFNalpha 6 promoter. At 24 h after infection, cells were infected with NDV for 12 h, and extracts were assayed for luciferase activity. Mean values from a representative experiment are expressed as fold induction relative to cells transfected with an empty vector after normalization to co-transfected beta -galactosidase.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphorylation is considered the major posttranslational modification responsible for activating signal transduction pathways. However, acetylation has been recently shown to be a widespread mechanism involved in regulating transcription factor activity. Here we show that IRF7, a transducer of a virus-mediated signaling pathway, is acetylated on lysine 92 within the DNA-binding domain by the acetyltransferase PCAF. Moreover, acetylation of lysine 92 impaired DNA binding ability and thus decreased transcriptional activity.

Our work is the first report of mapping an acetylation target residue for a protein of the IRF family. As mentioned above, IRF1 and 2 have been reported to be acetylated by p300 and PCAF within the DBD, but no alteration of DNA binding activity was observed (24). Moreover, the target residue(s) of acetylation were not mapped and therefore the correspondence between the acetylation of IRF1, IRF2, and IRF7 cannot be established. Recently, Suhara et al. (26) provided evidence that p300 had a direct contribution to the binding of IRF3 to DNA and that p300 was capable of acetylating IRF3 in vitro but only when IRF3 was present as a dimer in the holocomplex. The authors also suggested that acetylation of IRF3 was fundamental for activation of the holocomplex because a p300 HAT mutant failed to confer DNA binding activity. It is worth noting that acetylation by HAT enzymes seems to be very specific because p300 acetylates IRF3 but is not able to acetylate IRF7 and that PCAF shows an inverse specificity. Furthermore, these two acetylation events, which most likely take place on different sites, have opposite effects on the DNA binding ability of IRF3 and IRF7.

It is interesting to point out that, whereas an increase in activity has been observed upon acetylation of most transcription factors, some factors like HMGI(Y), YY1, and CDP/cut show decreased DNA binding when acetylated within their DNA-binding domain (27-29). The effect of acetylation on DNA binding appears to correlate with the functional domain where it takes place. Although increased DNA binding generally results from acetylation in a domain nearby the DNA-binding domain (E2F, EKLF, and p53), acetylation of lysine residues within the DNA-binding domain has an inhibitory effect on DNA binding. As reported for other DNA-binding proteins, many of the residues contacting the negatively charged DNA backbone are positively charged lysine and arginine residues. According to the crystal structure of the IRF1 DNA-binding domain bound to a DNA element from the interferon-beta promoter, lysine 78 (corresponding to lysine 92 in IRF7) is responsible for stabilizing the protein-DNA complex through hydrogen bonds (30). The decreased DNA binding ability of IRF7 upon acetylation can be likely explained by the neutralization of the positive charge of lysine 92 that is responsible for tightening the bonds between the transcriptional complex and promoter.

Though the mechanism driving IRF7 acetylation remains to be investigated, one can hypothesize that this phenomenon could be part of an auto-regulatory loop. Indeed, as an initial response to viral infection, cells produce a spectrum of early inflammatory cytokines, including interferon, that can both activate immune cells and directly inhibit viral replication. Host response to viral infection is potent and can be deleterious to the cell; thus it is essential for cell survival that this response be regulated in a precise spatial and temporal manner. It has been shown that, in the context of the interferon beta  enhanceosome, acetylation of HMGI(Y) on lysine 65 by CBP leads to destabilization and disassembly of the transcriptional complex (27). Our results favor the hypothesis that acetylation of IRF7 may play a similar role in disrupting the transcriptional complex bound to interferon alpha  promoters and turning off type I interferon gene induction. Alternatively, basal acetylation of IRF7 may be a regulatory step that prevents non-activated IRF7 from binding DNA with high affinity in the absence of the proper stimulus that will lead to its deacetylation. The kinetics and nature of the different stimuli leading to full activation of IRF7 and disruption of the active complex are not fully clarified and need further characterization. Thus, acetylation is likely to be a common mechanism for type I interferon gene repression.

It is also notable that acetylation of IRF7 occurs in a region that distinguishes its DNA binding from that of IRF3. Although IRF3 displays relatively strong DNA binding, it has a weak transactivation domain that appears to be completely dependent on p300 for induction of gene expression. In contrast, IRF7 binds weakly to DNA due to a rapid off rate, and this binding can be further reduced by acetylation of lysine 92. However, the potent transactivation domain of IRF7 that functions independently from known co-activator HAT proteins produces robust induction of IFNalpha genes following viral infection.

    ACKNOWLEDGEMENTS

We thank Y. Nakatani, R. Schiltz, S. Roth, M. Rosenfeld, and E. Verdin for the gift of plasmids. We thank Gregory David for helpful advice and critical reading of the manuscript. We thank Helene Collandre for helpful discussions.

    FOOTNOTES

* This work was supported in part by grants from the Association sur la Recherche contre le Cancer (ARC) (to I. M.), by Grant R01 A146503 from the National Institute of Health, and by Grant 9951033T from the American Heart Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of a fellowship from ARC.

** To whom correspondence should be addressed: Dept. of Pathology, New York University School of Medicine, 550 First Ave., MSB 556, New York, NY 10016. Tel.: 212-263-8705; Fax: 212-263-8211; E-mail: isabellemarie@hotmail.com.

Published, JBC Papers in Press, October 8, 2002, DOI 10.1074/jbc.M207484200

    ABBREVIATIONS

The abbreviations used are: IRF, interferon regulatory factor; IFN, interferon; HAT, histone acetyltransferase; DBD, DNA-binding domain; CBP, CREB-binding protein; PCAF, p300/CBP-associated factor; HMG, high mobility group; acetylCoA, acetylcoenzyme A; ISRE, interferon-stimulated response element; ISG, interferon-stimulated gene; EMSA, electromobility shift assay; WT, wild type; NDV, Newcastle disease virus; GST, glutathione S-transferase; CREB, cAMP-response element-binding protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Nguyen, H., Hiscott, J., and Pitha, P. M. (1997) Cytokine Growth Factor Rev. 8, 293-312[CrossRef][Medline] [Order article via Infotrieve]
2. Nehyba, J., Hrdlickova, R., Burnside, J., and Bose, H. R., Jr. (2002) Mol. Cell. Biol. 22, 3942-3957[Abstract/Free Full Text]
3. Barnes, B., Lubyova, B., and Pitha, P. M. (2002) J. Interferon Cytokine Res. 22, 59-71[CrossRef][Medline] [Order article via Infotrieve]
4. Veals, S. A., Schindler, C., Leonard, D., Fu, X. Y., Aebersold, R., Darnell, J. E., Jr., and Levy, D. E. (1992) Mol. Cell. Biol. 12, 3315-3324[Abstract/Free Full Text]
5. Marie, I., Durbin, J. E., and Levy, D. E. (1998) EMBO J. 17, 6660-6669[CrossRef][Medline] [Order article via Infotrieve]
6. Wathelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M., and Maniatis, T. (1998) Mol. Cell 1, 507-518[CrossRef][Medline] [Order article via Infotrieve]
7. Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., and Fujita, T. (1998) EMBO J. 17, 1087-1095[CrossRef][Medline] [Order article via Infotrieve]
8. Au, W. C., Moore, P. A., LaFleur, D. W., Tombal, B., and Pitha, P. M. (1998) J. Biol. Chem. 273, 29210-29217[Abstract/Free Full Text]
9. Lin, R., Heylbroeck, C., Pitha, P. M., and Hiscott, J. (1998) Mol. Cell. Biol. 18, 2986-2996[Abstract/Free Full Text]
10. Marie, I., Smith, E., Prakash, A., and Levy, D. E. (2000) Mol. Cell. Biol. 20, 8803-8814[Abstract/Free Full Text]
11. Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., and Tanaka, N. (1998) FEBS Lett. 441, 106-110[CrossRef][Medline] [Order article via Infotrieve]
12. Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., and Taniguchi, T. (2000) Immunity 13, 539-548[CrossRef][Medline] [Order article via Infotrieve]
13. Lin, R., Mamane, Y., and Hiscott, J. (2000) J. Biol. Chem. 275, 34320-34327[Abstract/Free Full Text]
14. Sterner, D. E., and Berger, S. L. (2000) Microbiol. Mol. Biol. Rev. 64, 435-459[Abstract/Free Full Text]
15. Kouzarides, T. (1999) Curr. Opin. Genet. Dev. 9, 40-48[CrossRef][Medline] [Order article via Infotrieve]
16. Gu, W., and Roeder, R. G. (1997) Cell 90, 595-606[CrossRef][Medline] [Order article via Infotrieve]
17. Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A., and Kouzarides, T. (2000) EMBO J. 19, 662-671[CrossRef][Medline] [Order article via Infotrieve]
18. Chen, H., Lin, R. J., Xie, W., Wilpitz, D., and Evans, R. M. (1999) Cell 98, 675-686[CrossRef][Medline] [Order article via Infotrieve]
19. Takemura, R., Okabe, S., Umeyama, T., Kanai, Y., Cowan, N. J., and Hirokawa, N. (1992) J. Cell Sci. 103, 953-964[Abstract/Free Full Text]
20. Silvennoinen, O., Schindler, C., Schlessinger, J., and Levy, D. E. (1993) Science 261, 1736-1739[Abstract/Free Full Text]
21. Levy, D. E. (1998) Methods 15, 167-174[CrossRef][Medline] [Order article via Infotrieve]
22. Kessler, D. S., Veals, S. A., Fu, X. Y., and Levy, D. E. (1990) Genes Dev. 4, 1753-1765[Abstract/Free Full Text]
23. Paulson, M., Press, C., Smith, E., Tanese, N., and Levy, D. E. (2002) Nat. Cell. Biol. 4, 140-147[CrossRef][Medline] [Order article via Infotrieve]
24. Masumi, A., and Ozato, K. (2001) J. Biol. Chem. 276, 20973-20980[Abstract/Free Full Text]
25. Herrera, J. E., Bergel, M., Yang, X. J., Nakatani, Y., and Bustin, M. (1997) J. Biol. Chem. 272, 27253-27258[Abstract/Free Full Text]
26. Suhara, W., Yoneyama, M., Kitabayashi, I., and Fujita, T. (2002) J. Biol. Chem. 277, 22304-22313[Abstract/Free Full Text]
27. Munshi, N., Merika, M., Yie, J., Senger, K., Chen, G., and Thanos, D. (1998) Mol. Cell 2, 457-467[CrossRef][Medline] [Order article via Infotrieve]
28. Yao, Y. L., Yang, W. M., and Seto, E. (2001) Mol. Cell. Biol. 21, 5979-5991[Abstract/Free Full Text]
29. Li, S., Aufiero, B., Schiltz, R. L., and Walsh, M. J. (2000) Proc. Natl. Acad. Sci. U. S. A 97, 7166-7171[Abstract/Free Full Text]
30. Escalante, C. R., Yie, J., Thanos, D., and Aggarwal, A. K. (1998) Nature 391, 103-106[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
A. Sabo, M. Lusic, A. Cereseto, and M. Giacca
Acetylation of Conserved Lysines in the Catalytic Core of Cyclin-Dependent Kinase 9 Inhibits Kinase Activity and Regulates Transcription
Mol. Cell. Biol., April 1, 2008; 28(7): 2201 - 2212.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Ozato, P. Tailor, and T. Kubota
The Interferon Regulatory Factor Family in Host Defense: Mechanism of Action
J. Biol. Chem., July 13, 2007; 282(28): 20065 - 20069.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
C. A. Sariol, J. L. Munoz-Jordan, K. Abel, L. C. Rosado, P. Pantoja, L. Giavedoni, I. V. Rodriguez, L. J. White, M. Martinez, T. Arana, et al.
Transcriptional Activation of Interferon-Stimulated Genes but Not of Cytokine Genes after Primary Infection of Rhesus Macaques with Dengue Virus Type 1
Clin. Vaccine Immunol., June 1, 2007; 14(6): 756 - 766.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-S. Chen, Y.-C. Wang, H.-C. Yang, P.-H. Huang, S. K. Kulp, C.-C. Yang, Y.-S. Lu, S. Matsuyama, C.-Y. Chen, and C.-S. Chen
Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation
Cancer Res., June 1, 2007; 67(11): 5318 - 5327.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. L. Fanning, T. C. George, D. Feng, S. B. Feldman, N. J. Megjugorac, A. G. Izaguirre, and P. Fitzgerald-Bocarsly
Receptor Cross-Linking on Human Plasmacytoid Dendritic Cells Leads to the Regulation of IFN-{alpha} Production
J. Immunol., November 1, 2006; 177(9): 5829 - 5839.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S.-D. Chou, A. N. H. Khan, W. J. Magner, and T. B. Tomasi
Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells
Int. Immunol., November 1, 2005; 17(11): 1483 - 1494.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Sakamoto, R. Potla, and A. C. Larner
Histone Deacetylase Activity Is Required to Recruit RNA Polymerase II to the Promoters of Selected Interferon-stimulated Early Response Genes
J. Biol. Chem., September 24, 2004; 279(39): 40362 - 40367.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Lubyova, M. J. Kellum, A. J. Frisancho, and P. M. Pitha
Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Stimulates the Transcriptional Activity of Cellular IRF-3 and IRF-7
J. Biol. Chem., February 27, 2004; 279(9): 7643 - 7654.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Buryskova, M. Pospisek, A. Grothey, T. Simmet, and L. Burysek
Intracellular Interleukin-1{alpha} Functionally Interacts with Histone Acetyltransferase Complexes
J. Biol. Chem., February 6, 2004; 279(6): 4017 - 4026.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Nusinzon and C. M. Horvath
Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1
PNAS, December 9, 2003; 100(25): 14742 - 14747.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Masumi, Y. Yamakawa, H. Fukazawa, K. Ozato, and K. Komuro
Interferon Regulatory Factor-2 Regulates Cell Growth through Its Acetylation
J. Biol. Chem., July 3, 2003; 278(28): 25401 - 25407.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. J. Barnes, A. E. Field, and P. M. Pitha-Rowe
Virus-induced Heterodimer Formation between IRF-5 and IRF-7 Modulates Assembly of the IFNA Enhanceosome in Vivo and Transcriptional Activity of IFNA Genes
J. Biol. Chem., May 2, 2003; 278(19): 16630 - 16641.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/51/49417    most recent
M207484200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caillaud, A.
Right arrow Articles by Marié, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caillaud, A.
Right arrow Articles by Marié, I.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.